{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:46:11Z","timestamp":1793249171471,"version":"4.5.0"},"reference-count":236,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2022ZDZX0023"],"award-info":[{"award-number":["2022ZDZX0023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple system atrophy is a rare, debilitating, adult-onset neurodegenerative disorder that manifests clinically as a diverse combination of parkinsonism, cerebellar ataxia, and autonomic dysfunction. It is pathologically characterized by oligodendroglial cytoplasmic inclusions containing abnormally aggregated \u03b1-synuclein. According to the updated Movement Disorder Society diagnostic criteria for multiple system atrophy, the diagnosis of clinically established multiple system atrophy requires the manifestation of autonomic dysfunction in combination with poorly levo-dopa responsive parkinsonism and\/or cerebellar syndrome. Although symptomatic management of multiple system atrophy can substantially improve quality of life, therapeutic benefits are often limited, ephemeral, and they fail to modify the disease progression and eradicate underlying causes. Consequently, effective breakthrough treatments that target the causes of disease are needed. Numerous preclinical and clinical studies are currently focusing on a set of hallmarks of neurodegenerative diseases to slow or halt the progression of multiple system atrophy: pathological protein aggregation, synaptic dysfunction, aberrant proteostasis, neuronal inflammation, and neuronal cell death. Meanwhile, specific biomarkers and measurements with higher specificity and sensitivity are being developed for the diagnosis of multiple system atrophy, particularly for early detection of the disease. More intriguingly, a growing number of new disease-modifying candidates, which can be used to design multi-targeted, personalized treatment in patients, are being investigated, notwithstanding the failure of most previous attempts.<\/jats:p>","DOI":"10.1007\/s00415-024-12269-5","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T06:03:48Z","timestamp":1710396228000},"page":"2324-2344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials"],"prefix":"10.1007","volume":"271","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-1151","authenticated-orcid":false,"given":"Huifang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"issue":"3","key":"12269_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249\u2013263","journal-title":"N Engl J Med"},{"issue":"1","key":"12269_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2990.2011.01234.x","volume":"38","author":"Z Ahmed","year":"2012","unstructured":"Ahmed Z et al (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38(1):4\u201324","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1\u20133","key":"12269_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0022-510X(89)90219-0","volume":"94","author":"MI Papp","year":"1989","unstructured":"Papp MI, Kahn JE, Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94(1\u20133):79\u2013100","journal-title":"J Neurol Sci"},{"issue":"3","key":"12269_CR4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JAD-170397","volume":"62","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA (2018) Multiple system atrophy: an oligodendroglioneural synucleinopathy1. J Alzheimers Dis 62(3):1141\u20131179","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"12269_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3940(98)00504-7","volume":"251","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG et al (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson\u2019s disease and dementia with Lewy bodies. Neurosci Lett 251(3):205\u2013208","journal-title":"Neurosci Lett"},{"issue":"6","key":"12269_CR6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12311-015-0728-y","volume":"15","author":"DJ Lin","year":"2016","unstructured":"Lin DJ, Hermann KL, Schmahmann JD (2016) The diagnosis and natural history of multiple system atrophy. Cerebellar Type Cerebellum 15(6):663\u2013679","journal-title":"Cerebellar Type Cerebellum"},{"issue":"3","key":"12269_CR7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","volume":"12","author":"GK Wenning","year":"2013","unstructured":"Wenning GK et al (2013) The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 12(3):264\u2013274","journal-title":"Lancet Neurol"},{"issue":"7","key":"12269_CR8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","volume":"14","author":"PA Low","year":"2015","unstructured":"Low PA et al (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14(7):710\u2013719","journal-title":"Lancet Neurol"},{"key":"12269_CR9","first-page":"100183","volume":"8","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Prediction of early-wheelchair dependence in multiple system atrophy based on machine learning algorithm: a prospective cohort study. Clin Park Relat Disord 8:100183","journal-title":"Clin Park Relat Disord"},{"issue":"6","key":"12269_CR10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK et al (2022) The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord 37(6):1131\u20131148","journal-title":"Mov Disord"},{"key":"12269_CR11","doi-asserted-by":"crossref","first-page":"1200563","DOI":"10.3389\/fnagi.2023.1200563","volume":"15","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Diagnostic utility of movement disorder society criteria for multiple system atrophy. Front Aging Neurosci 15:1200563","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"12269_CR12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/jnnp-2012-302500","volume":"84","author":"A Bjornsdottir","year":"2013","unstructured":"Bjornsdottir A et al (2013) Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry 84(2):136\u2013140","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"12269_CR13","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1212\/WNL.49.5.1284","volume":"49","author":"JH Bower","year":"1997","unstructured":"Bower JH et al (1997) Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49(5):1284\u20131288","journal-title":"Neurology"},{"issue":"3","key":"12269_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/mds.22987","volume":"25","author":"J Linder","year":"2010","unstructured":"Linder J, Stenlund H, Forsgren L (2010) Incidence of Parkinson\u2019s disease and parkinsonism in northern Sweden: a population-based study. Mov Disord 25(3):341\u2013348","journal-title":"Mov Disord"},{"issue":"3","key":"12269_CR15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.22966","volume":"25","author":"Y Winter","year":"2010","unstructured":"Winter Y et al (2010) Incidence of Parkinson\u2019s disease and atypical parkinsonism: Russian population-based study. Mov Disord 25(3):349\u2013356","journal-title":"Mov Disord"},{"issue":"9192","key":"12269_CR16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(99)04137-9","volume":"354","author":"A Schrag","year":"1999","unstructured":"Schrag A, Ben-Shlomo Y, Quinn NP (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354(9192):1771\u20131775","journal-title":"Lancet"},{"issue":"4","key":"12269_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000078506","volume":"23","author":"V Chrysostome","year":"2004","unstructured":"Chrysostome V et al (2004) Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine. France Neuroepidemiology 23(4):201\u2013208","journal-title":"France Neuroepidemiology"},{"issue":"Pt 5","key":"12269_CR18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/brain\/awf117","volume":"125","author":"H Watanabe","year":"2002","unstructured":"Watanabe H et al (2002) Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125(Pt 5):1070\u20131083","journal-title":"Brain"},{"issue":"4","key":"12269_CR19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3233\/JPD-140434","volume":"4","author":"E Gatto","year":"2014","unstructured":"Gatto E et al (2014) Pan-American Consortium of Multiple System Atrophy (PANMSA) A Pan-American multicentre cohort study of multiple system atrophy. J Parkinsons Dis 4(4):693\u2013698","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"12269_CR20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archneur.64.4.545","volume":"64","author":"K Hara","year":"2007","unstructured":"Hara K et al (2007) Multiplex families with multiple system atrophy. Arch Neurol 64(4):545\u2013551","journal-title":"Arch Neurol"},{"issue":"4","key":"12269_CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/jnnp.2008.158949","volume":"80","author":"U Wullner","year":"2009","unstructured":"Wullner U et al (2009) Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 80(4):449\u2013450","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"12269_CR22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ana.21685","volume":"65","author":"SW Scholz","year":"2009","unstructured":"Scholz SW et al (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65(5):610\u2013614","journal-title":"Ann Neurol"},{"issue":"9","key":"12269_CR23","doi-asserted-by":"crossref","first-page":"e7114","DOI":"10.1371\/journal.pone.0007114","volume":"4","author":"A Al-Chalabi","year":"2009","unstructured":"Al-Chalabi A et al (2009) Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS ONE 4(9):e7114","journal-title":"PLoS ONE"},{"issue":"2","key":"12269_CR24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0304-3940(99)00475-9","volume":"270","author":"T Ozawa","year":"1999","unstructured":"Ozawa T et al (1999) No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett 270(2):110\u2013112","journal-title":"Neurosci Lett"},{"issue":"3","key":"12269_CR25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1212115","volume":"369","author":"Multiple-System Atrophy Research C","year":"2013","unstructured":"Multiple-System Atrophy Research C (2013) Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 369(3):233\u2013244","journal-title":"N Engl J Med"},{"issue":"15","key":"12269_CR26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1212\/WNL.0000000000003221","volume":"87","author":"A Sailer","year":"2016","unstructured":"Sailer A et al (2016) A genome-wide association study in multiple system atrophy. Neurology 87(15):1591\u20131598","journal-title":"Neurology"},{"issue":"1","key":"12269_CR27","first-page":"82","volume":"371","author":"J Mitsui","year":"2014","unstructured":"Mitsui J, Tsuji S (2014) Mutant COQ2 in multiple-system atrophy. N Engl J Med 371(1):82\u201383","journal-title":"N Engl J Med"},{"issue":"3","key":"12269_CR28","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10072-015-2414-8","volume":"37","author":"Q Zhao","year":"2016","unstructured":"Zhao Q et al (2016) Association of the COQ2 V393A variant with risk of multiple system atrophy in East Asians: a case-control study and meta-analysis of the literature. Neurol Sci 37(3):423\u2013430","journal-title":"Neurol Sci"},{"key":"12269_CR29","doi-asserted-by":"crossref","first-page":"117623","DOI":"10.1016\/j.jns.2021.117623","volume":"429","author":"KJ Porto","year":"2021","unstructured":"Porto KJ et al (2021) COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. J Neurol Sci 429:117623","journal-title":"J Neurol Sci"},{"issue":"2","key":"12269_CR30","first-page":"1222 e7-11","volume":"36","author":"YP Chen","year":"2015","unstructured":"Chen YP et al (2015) (2015) Mutation scanning of the COQ2 gene in ethnic Chinese patients with multiple-system atrophy. Neurobiol Aging 36(2):1222 e7\u201311","journal-title":"Neurobiol Aging"},{"issue":"8","key":"12269_CR31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/cns.12412","volume":"21","author":"XD Wen","year":"2015","unstructured":"Wen XD et al (2015) Mutation analysis of COQ2 in Chinese patients with cerebellar subtype of multiple system atrophy. CNS Neurosci Ther 21(8):626\u2013630","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"12269_CR32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jamaneurol.2013.5762","volume":"71","author":"JS Goldman","year":"2014","unstructured":"Goldman JS et al (2014) Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72. JAMA Neurol 71(6):771\u2013774","journal-title":"JAMA Neurol"},{"issue":"11","key":"12269_CR33","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00702-016-1598-2","volume":"123","author":"X Chen","year":"2016","unstructured":"Chen X et al (2016) C9ORF72 repeat expansions in Chinese patients with Parkinson\u2019s disease and multiple system atrophy. J Neural Transm (Vienna) 123(11):1341\u20131345","journal-title":"J Neural Transm (Vienna)"},{"issue":"17","key":"12269_CR34","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361(17):1651\u20131661","journal-title":"N Engl J Med"},{"key":"12269_CR35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuroscience.2016.02.007","volume":"320","author":"F Zhao","year":"2016","unstructured":"Zhao F et al (2016) Mutations of glucocerebrosidase gene and susceptibility to Parkinson\u2019s disease: an updated meta-analysis in a European population. Neuroscience 320:239\u2013246","journal-title":"Neuroscience"},{"issue":"4","key":"12269_CR36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/acn3.185","volume":"2","author":"J Mitsui","year":"2015","unstructured":"Mitsui J et al (2015) Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2(4):417\u2013426","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"12269_CR37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jocn.2012.01.055","volume":"20","author":"QY Sun","year":"2013","unstructured":"Sun QY et al (2013) Genetic association study of glucocerebrosidase gene L444P mutation in essential tremor and multiple system atrophy in mainland China. J Clin Neurosci 20(2):217\u2013219","journal-title":"J Clin Neurosci"},{"issue":"24","key":"12269_CR38","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1212\/WNL.0000000000001078","volume":"83","author":"MG Heckman","year":"2014","unstructured":"Heckman MG et al (2014) LRRK2 exonic variants and risk of multiple system atrophy. Neurology 83(24):2256\u20132261","journal-title":"Neurology"},{"issue":"2","key":"12269_CR39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.parkreldis.2014.11.022","volume":"21","author":"X Yuan","year":"2015","unstructured":"Yuan X et al (2015) An association analysis of the R1628P and G2385R polymorphisms of the LRRK2 gene in multiple system atrophy in a Chinese population. Parkinsonism Relat Disord 21(2):147\u2013149","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"12269_CR40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.parkreldis.2008.07.010","volume":"15","author":"K Hasegawa","year":"2009","unstructured":"Hasegawa K et al (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15(4):300\u2013306","journal-title":"Parkinsonism Relat Disord"},{"key":"12269_CR41","doi-asserted-by":"crossref","first-page":"201 e1","DOI":"10.1016\/j.neurobiolaging.2018.03.018","volume":"67","author":"X Gu","year":"2018","unstructured":"Gu X et al (2018) Analysis of GWAS-linked variants in multiple system atrophy. Neurobiol Aging 67:201 e1-201 e4","journal-title":"Neurobiol Aging"},{"issue":"14","key":"12269_CR42","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/mds.26052","volume":"29","author":"KA Jellinger","year":"2014","unstructured":"Jellinger KA (2014) Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord 29(14):1720\u20131741","journal-title":"Mov Disord"},{"issue":"Suppl 6","key":"12269_CR43","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.10557","volume":"18","author":"KA Jellinger","year":"2003","unstructured":"Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18(Suppl 6):S2-12","journal-title":"Mov Disord"},{"issue":"3","key":"12269_CR44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410440324","volume":"44","author":"PH Tu","year":"1998","unstructured":"Tu PH et al (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44(3):415\u2013422","journal-title":"Ann Neurol"},{"issue":"2","key":"12269_CR45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s004010100367","volume":"102","author":"T Ozawa","year":"2001","unstructured":"Ozawa T et al (2001) Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol 102(2):188\u2013190","journal-title":"Acta Neuropathol"},{"issue":"12","key":"12269_CR46","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00702-005-0378-1","volume":"112","author":"DW Miller","year":"2005","unstructured":"Miller DW et al (2005) Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) 112(12):1613\u20131624","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"12269_CR47","first-page":"145","volume":"55","author":"H Jin","year":"2008","unstructured":"Jin H et al (2008) Analyses of copy number and mRNA expression level of the alpha-synuclein gene in multiple system atrophy. J Med Dent Sci 55(1):145\u2013153","journal-title":"J Med Dent Sci"},{"key":"12269_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autneu.2017.11.002","volume":"211","author":"E Valera","year":"2018","unstructured":"Valera E, Masliah E (2018) The neuropathology of multiple system atrophy and its therapeutic implications. Auton Neurosci 211:1\u20136","journal-title":"Auton Neurosci"},{"issue":"1","key":"12269_CR49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13024-022-00579-z","volume":"17","author":"K Reddy","year":"2022","unstructured":"Reddy K, Dieriks BV (2022) Multiple system atrophy: alpha-Synuclein strains at the neuron-oligodendrocyte crossroad. Mol Neurodegener 17(1):77","journal-title":"Mol Neurodegener"},{"issue":"3","key":"12269_CR50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1750-3639.2012.00637.x","volume":"23","author":"Z Ahmed","year":"2013","unstructured":"Ahmed Z et al (2013) Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson\u2019s disease. Brain Pathol 23(3):263\u2013273","journal-title":"Brain Pathol"},{"issue":"6","key":"12269_CR51","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41583-023-00697-7","volume":"24","author":"N Stefanova","year":"2023","unstructured":"Stefanova N, Wenning GK (2023) Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms. Nat Rev Neurosci 24(6):334\u2013346","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"12269_CR52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/biom12070957","volume":"12","author":"P Mavroeidi","year":"2022","unstructured":"Mavroeidi P et al (2022) Exosomes in alpha-synucleinopathies: propagators of pathology or potential candidates for nanotherapeutics? Biomolecules 12(7):957","journal-title":"Biomolecules"},{"issue":"2","key":"12269_CR53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-006-0167-4","volume":"113","author":"GG Kovacs","year":"2007","unstructured":"Kovacs GG et al (2007) The brain-specific protein TPPP\/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathol 113(2):153\u2013161","journal-title":"Acta Neuropathol"},{"issue":"4","key":"12269_CR54","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2353\/ajpath.2007.070201","volume":"171","author":"YJ Song","year":"2007","unstructured":"Song YJ et al (2007) p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171(4):1291\u20131303","journal-title":"Am J Pathol"},{"key":"12269_CR55","first-page":"136","volume":"2","author":"K Ota","year":"2014","unstructured":"Ota K et al (2014) Relocation of p25alpha\/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy. Acta Neuropathol Commun 2:136","journal-title":"Acta Neuropathol Commun"},{"key":"12269_CR56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fncel.2015.00163","volume":"9","author":"K Pukass","year":"2015","unstructured":"Pukass K, Richter-Landsberg C (2015) Inhibition of UCH-L1 in oligodendroglial cells results in microtubule stabilization and prevents alpha-synuclein aggregate formation by activating the autophagic pathway: implications for multiple system atrophy. Front Cell Neurosci 9:163","journal-title":"Front Cell Neurosci"},{"issue":"3\u20134","key":"12269_CR57","first-page":"117","volume":"58","author":"K Sugiura","year":"1995","unstructured":"Sugiura K et al (1995) Distribution of neuronal cytoplasmic inclusions in multiple system atrophy. Nagoya J Med Sci 58(3\u20134):117\u2013126","journal-title":"Nagoya J Med Sci"},{"key":"12269_CR58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fncel.2015.00437","volume":"9","author":"BD Vieira","year":"2015","unstructured":"Vieira BD et al (2015) Neuroinflammation in multiple system atrophy: response to and cause of alpha-synuclein aggregation. Front Cell Neurosci 9:437","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"12269_CR59","first-page":"1117","volume":"22","author":"NR McFarland","year":"2016","unstructured":"McFarland NR (2016) Diagnostic approach to atypical Parkinsonian syndromes. Continuum (Minneap Minn) 22(4):1117\u20131142","journal-title":"Continuum (Minneap Minn)"},{"issue":"8","key":"12269_CR60","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3233\/JPD-230095","volume":"13","author":"Q Jiang","year":"2023","unstructured":"Jiang Q et al (2023) Orthostatic hypotension in multiple system atrophy: related factors and disease prognosis. J Parkinsons Dis 13(8):1313\u20131320","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"12269_CR61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/jnnp.68.1.65","volume":"68","author":"R Sakakibara","year":"2000","unstructured":"Sakakibara R et al (2000) Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 68(1):65\u201369","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"12269_CR62","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/mds.20815","volume":"21","author":"T Ito","year":"2006","unstructured":"Ito T et al (2006) Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 21(6):816\u2013823","journal-title":"Mov Disord"},{"key":"12269_CR63","doi-asserted-by":"crossref","first-page":"117954682095341","DOI":"10.1177\/1179546820953415","volume":"14","author":"DK Kalra","year":"2020","unstructured":"Kalra DK, Raina A, Sohal S (2020) Neurogenic orthostatic hypotension: state of the art and therapeutic strategies. Clin Med Insights Cardiol 14:1179546820953415","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"12269_CR64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12883-018-1129-x","volume":"18","author":"DO Claassen","year":"2018","unstructured":"Claassen DO et al (2018) Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurol 18(1):125","journal-title":"BMC Neurol"},{"issue":"4","key":"12269_CR65","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s13311-020-00890-x","volume":"17","author":"MR Burns","year":"2020","unstructured":"Burns MR, McFarland NR (2020) Current management and emerging therapies in multiple system atrophy. Neurotherapeutics 17(4):1582\u20131602","journal-title":"Neurotherapeutics"},{"issue":"2","key":"12269_CR66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acn3.50987","volume":"7","author":"S Eschlb\u00f6ck","year":"2020","unstructured":"Eschlb\u00f6ck S et al (2020) Cognition in multiple system atrophy: a single-center cohort study. Ann Clin Transl Neurol 7(2):219\u2013228","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"12269_CR67","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/mds.25880","volume":"29","author":"I Stankovic","year":"2014","unstructured":"Stankovic I et al (2014) Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. Mov Disord 29(7):857\u2013867","journal-title":"Mov Disord"},{"issue":"8","key":"12269_CR68","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/mds.20450","volume":"20","author":"LM Benrud-Larson","year":"2005","unstructured":"Benrud-Larson LM et al (2005) Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 20(8):951\u2013957","journal-title":"Mov Disord"},{"issue":"1","key":"12269_CR69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ane.12804","volume":"137","author":"LY Zhang","year":"2018","unstructured":"Zhang LY et al (2018) Depression and anxiety in multiple system atrophy. Acta Neurol Scand 137(1):33\u201337","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"12269_CR70","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12916-023-03176-z","volume":"21","author":"L Zhang","year":"2023","unstructured":"Zhang L et al (2023) Longitudinal evolution of sleep disturbances in early multiple system atrophy: a 2-year prospective cohort study. BMC Med 21(1):454","journal-title":"BMC Med"},{"issue":"6","key":"12269_CR71","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CM9.0000000000001211","volume":"134","author":"JY Lin","year":"2020","unstructured":"Lin JY et al (2020) Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity. Chin Med J (Engl) 134(6):690\u2013698","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"12269_CR72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-015-0279-9","volume":"25","author":"JA Palma","year":"2015","unstructured":"Palma JA et al (2015) Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res 25(1):69\u201375","journal-title":"Clin Auton Res"},{"issue":"6","key":"12269_CR73","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/WNL.0b013e3181ec7fac","volume":"75","author":"DO Claassen","year":"2010","unstructured":"Claassen DO et al (2010) REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 75(6):494\u2013499","journal-title":"Neurology"},{"issue":"14","key":"12269_CR74","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1212\/WNL.0000000000008208","volume":"93","author":"P Cortelli","year":"2019","unstructured":"Cortelli P et al (2019) Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. Neurology 93(14):630\u2013639","journal-title":"Neurology"},{"issue":"2\u20133","key":"12269_CR75","first-page":"189","volume":"74","author":"S Gilman","year":"1998","unstructured":"Gilman S et al (1998) Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 74(2\u20133):189\u2013192","journal-title":"J Auton Nerv Syst"},{"issue":"9","key":"12269_CR76","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670\u2013676","journal-title":"Neurology"},{"issue":"15","key":"12269_CR77","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.22826","volume":"24","author":"Y Osaki","year":"2009","unstructured":"Osaki Y et al (2009) A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 24(15):2272\u20132276","journal-title":"Mov Disord"},{"issue":"7","key":"12269_CR78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/mds.27701","volume":"34","author":"I Stankovic","year":"2019","unstructured":"Stankovic I et al (2019) A critique of the second consensus criteria for multiple system atrophy. Mov Disord 34(7):975\u2013984","journal-title":"Mov Disord"},{"key":"12269_CR79","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mds.29304","volume":"38","author":"S Virameteekul","year":"2023","unstructured":"Virameteekul S et al (2023) Pathological validation of the MDS criteria for the diagnosis of multiple system atrophy. Mov Disord 38:444\u2013452","journal-title":"Mov Disord"},{"issue":"6","key":"12269_CR80","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2990.2007.00907.x","volume":"33","author":"Trojanowski, J.Q., T. Revesz, and M.S.A. Neuropathology Working Group on","year":"2007","unstructured":"Trojanowski, J.Q., T. Revesz, and M.S.A. Neuropathology Working Group on (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33(6):615\u2013620","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"12269_CR81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10286-020-00738-6","volume":"31","author":"RD Thijs","year":"2021","unstructured":"Thijs RD et al (2021) Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness\u202f: consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). Clin Auton Res 31(3):369\u2013384","journal-title":"Clin Auton Res"},{"issue":"Suppl 2","key":"12269_CR82","first-page":"S732","volume":"24","author":"O Rascol","year":"2009","unstructured":"Rascol O, Schelosky L (2009) 123I-metaiodobenzylguanidine scintigraphy in Parkinson\u2019s disease and related disorders. Mov Disord 24(Suppl 2):S732\u2013S741","journal-title":"Mov Disord"},{"issue":"2","key":"12269_CR83","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.24877","volume":"81","author":"H Kaufmann","year":"2017","unstructured":"Kaufmann H et al (2017) Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol 81(2):287\u2013297","journal-title":"Ann Neurol"},{"issue":"12","key":"12269_CR84","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1212\/WNL.0000000000003737","volume":"88","author":"W Singer","year":"2017","unstructured":"Singer W et al (2017) Pure autonomic failure: predictors of conversion to clinical CNS involvement. Neurology 88(12):1129\u20131136","journal-title":"Neurology"},{"key":"12269_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1048895\/full","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Pellecchia MT, Sakakibara R (2022) Autonomic dysfunction in multiple system atrophy. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2022.1048895\/full","journal-title":"Front Neurol"},{"issue":"12","key":"12269_CR86","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/mds.27917","volume":"34","author":"A Fanciulli","year":"2019","unstructured":"Fanciulli A et al (2019) Urinary retention discriminates multiple system atrophy from Parkinson\u2019s disease. Mov Disord 34(12):1926\u20131928","journal-title":"Mov Disord"},{"issue":"4","key":"12269_CR87","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00415-018-9121-3","volume":"266","author":"V Chelban","year":"2019","unstructured":"Chelban V et al (2019) An update on advances in magnetic resonance imaging of multiple system atrophy. J Neurol 266(4):1036\u20131045","journal-title":"J Neurol"},{"key":"12269_CR88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2377-12-39","volume":"12","author":"KK Tha","year":"2012","unstructured":"Tha KK et al (2012) Hyperintense putaminal rim at 1.5 T: prevalence in normal subjects and distinguishing features from multiple system atrophy. BMC Neurol 12:39","journal-title":"BMC Neurol"},{"issue":"3","key":"12269_CR89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0720-048X(03)00214-6","volume":"51","author":"R Juh","year":"2004","unstructured":"Juh R et al (2004) Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 51(3):223\u2013233","journal-title":"Eur J Radiol"},{"key":"12269_CR90","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S et al (2022) In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology 208:108985","journal-title":"Neuropharmacology"},{"issue":"9","key":"12269_CR91","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/ph14090847","volume":"14","author":"S Korat","year":"2021","unstructured":"Korat S et al (2021) Alpha-synuclein PET tracer development-an overview about current efforts. Pharmaceuticals (Basel) 14(9):847","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"12269_CR92","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/14737175.2017.1392239","volume":"17","author":"KA Jellinger","year":"2017","unstructured":"Jellinger KA (2017) Potential clinical utility of multiple system atrophy biomarkers. Expert Rev Neurother 17(12):1189\u20131208","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"12269_CR93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-023-00370-0","volume":"12","author":"L Wan","year":"2023","unstructured":"Wan L et al (2023) Multidimensional biomarkers for multiple system atrophy: an update and future directions. Transl Neurodegener 12(1):38","journal-title":"Transl Neurodegener"},{"key":"12269_CR94","doi-asserted-by":"crossref","first-page":"1210220","DOI":"10.3389\/fneur.2023.1210220","volume":"14","author":"M Goolla","year":"2023","unstructured":"Goolla M et al (2023) Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers. Front Neurol 14:1210220","journal-title":"Front Neurol"},{"issue":"8","key":"12269_CR95","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00415-020-09781-9","volume":"268","author":"S Cong","year":"2021","unstructured":"Cong S et al (2021) Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis. J Neurol 268(8):2703\u20132712","journal-title":"J Neurol"},{"key":"12269_CR96","first-page":"8740419","volume":"2020","author":"XY Li","year":"2020","unstructured":"Li XY et al (2020) Phosphorylated alpha-synuclein in red blood cells as a potential diagnostic biomarker for multiple system atrophy: a pilot study. Parkinsons Dis 2020:8740419","journal-title":"Parkinsons Dis"},{"issue":"2","key":"12269_CR97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3988\/jcn.2019.15.2.135","volume":"15","author":"JY Kim","year":"2019","unstructured":"Kim JY et al (2019) Alpha-synuclein in skin nerve fibers as a biomarker for alpha-synucleinopathies. J Clin Neurol 15(2):135\u2013142","journal-title":"J Clin Neurol"},{"issue":"2","key":"12269_CR98","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","volume":"74","author":"M Shahnawaz","year":"2017","unstructured":"Shahnawaz M et al (2017) Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol 74(2):163\u2013172","journal-title":"JAMA Neurol"},{"issue":"7794","key":"12269_CR99","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M et al (2020) Discriminating alpha-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578(7794):273\u2013277","journal-title":"Nature"},{"issue":"1","key":"12269_CR100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140(1):49\u201362","journal-title":"Acta Neuropathol"},{"issue":"1","key":"12269_CR101","first-page":"1","volume":"78","author":"Z Wang","year":"2020","unstructured":"Wang Z et al (2020) Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol 78(1):1\u201311","journal-title":"JAMA Neurol"},{"issue":"3","key":"12269_CR102","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/mds.28912","volume":"37","author":"I Martinez-Valbuena","year":"2022","unstructured":"Martinez-Valbuena I et al (2022) Combining Skin alpha-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson\u2019s disease. Mov Disord 37(3):648\u2013650","journal-title":"Mov Disord"},{"key":"12269_CR103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-019-0164-x","volume":"8","author":"CMG De Luca","year":"2019","unstructured":"De Luca CMG et al (2019) Efficient RT-QuIC seeding activity for alpha-synuclein in olfactory mucosa samples of patients with Parkinson\u2019s disease and multiple system atrophy. Transl Neurodegener 8:24","journal-title":"Transl Neurodegener"},{"issue":"2","key":"12269_CR104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/mds.27907","volume":"35","author":"S Manne","year":"2020","unstructured":"Manne S et al (2020) Alpha-synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson\u2019s disease patients. Mov Disord 35(2):268\u2013278","journal-title":"Mov Disord"},{"issue":"3","key":"12269_CR105","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/brain\/awac124","volume":"146","author":"V Donadio","year":"2023","unstructured":"Donadio V et al (2023) Phosphorylated alpha-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. Brain 146(3):1065\u20131074","journal-title":"Brain"},{"issue":"2","key":"12269_CR106","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/mds.28847","volume":"37","author":"L Zhang","year":"2022","unstructured":"Zhang L et al (2022) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Mov Disord 37(2):421\u2013426","journal-title":"Mov Disord"},{"issue":"7","key":"12269_CR107","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/cells8070727","volume":"8","author":"LM Doyle","year":"2019","unstructured":"Doyle LM, Wang MZ (2019) Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 8(7):727","journal-title":"Cells"},{"issue":"6","key":"12269_CR108","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/brain\/awaa110","volume":"143","author":"Z Yu","year":"2020","unstructured":"Yu Z et al (2020) Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction. Brain 143(6):1780\u20131797","journal-title":"Brain"},{"issue":"3","key":"12269_CR109","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00401-021-02324-0","volume":"142","author":"S Dutta","year":"2021","unstructured":"Dutta S et al (2021) alpha-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson\u2019s disease from multiple system atrophy. Acta Neuropathol 142(3):495\u2013511","journal-title":"Acta Neuropathol"},{"key":"12269_CR110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2020.05.018","volume":"75","author":"S Koga","year":"2020","unstructured":"Koga S et al (2020) Cerebrovascular pathology and misdiagnosis of multiple system atrophy: an autopsy study. Parkinsonism Relat Disord 75:34\u201340","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 12","key":"12269_CR111","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1002\/mds.20537","volume":"20","author":"KA Jellinger","year":"2005","unstructured":"Jellinger KA, Seppi K, Wenning GK (2005) Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20(Suppl 12):S29-36","journal-title":"Mov Disord"},{"issue":"Pt 12","key":"12269_CR112","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/brain\/awh303","volume":"127","author":"T Ozawa","year":"2004","unstructured":"Ozawa T et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127(Pt 12):2657\u20132671","journal-title":"Brain"},{"issue":"3","key":"12269_CR113","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mds.27344","volume":"33","author":"JA Palma","year":"2018","unstructured":"Palma JA, Kaufmann H (2018) Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord 33(3):372\u2013390","journal-title":"Mov Disord"},{"key":"12269_CR114","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12311-022-01411-6","volume":"22","author":"A Grossauer","year":"2022","unstructured":"Grossauer A et al (2022) Symptomatic care in multiple system atrophy: state of the art. Cerebellum 22:433\u2013446","journal-title":"Cerebellum"},{"issue":"1","key":"12269_CR115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-022-00382-6","volume":"8","author":"W Poewe","year":"2022","unstructured":"Poewe W et al (2022) Multiple system atrophy. Nat Rev Dis Primers 8(1):56","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"12269_CR116","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3233\/JPD-223183","volume":"12","author":"V Sidoroff","year":"2022","unstructured":"Sidoroff V et al (2022) Disease-modifying therapies for multiple system atrophy: where are we in 2022? J Parkinsons Dis 12(5):1369\u20131387","journal-title":"J Parkinsons Dis"},{"key":"12269_CR117","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","volume":"10","author":"M Mandler","year":"2015","unstructured":"Mandler M et al (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10:10","journal-title":"Mol Neurodegener"},{"issue":"7","key":"12269_CR118","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","volume":"19","author":"D Volc","year":"2020","unstructured":"Volc D et al (2020) Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol 19(7):591\u2013600","journal-title":"Lancet Neurol"},{"issue":"11","key":"12269_CR119","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","volume":"35","author":"WG Meissner","year":"2020","unstructured":"Meissner WG et al (2020) A Phase 1 randomized trial of specific active alpha-synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord 35(11):1957\u20131965","journal-title":"Mov Disord"},{"issue":"2","key":"12269_CR120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","volume":"32","author":"DB Schenk","year":"2017","unstructured":"Schenk DB et al (2017) First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord 32(2):211\u2013218","journal-title":"Mov Disord"},{"issue":"10","key":"12269_CR121","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J et al (2018) Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol 75(10):1206\u20131214","journal-title":"JAMA Neurol"},{"issue":"5","key":"12269_CR122","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G et al (2022) Trial of Prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med 387(5):421\u2013432","journal-title":"N Engl J Med"},{"issue":"5","key":"12269_CR123","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang AE et al (2022) Trial of cinpanemab in early Parkinson\u2019s disease. N Engl J Med 387(5):408\u2013420","journal-title":"N Engl J Med"},{"issue":"10","key":"12269_CR124","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19(10):673\u2013694","journal-title":"Nat Rev Drug Discov"},{"key":"12269_CR125","doi-asserted-by":"publisher","DOI":"10.2217\/frd-2021-0008","author":"J Igarashi","year":"2022","unstructured":"Igarashi J, Niwa Y, Sugiyama D (2022) Research and development of oligonucleotide therapeutics in Japan for rare diseases. Future Med. https:\/\/doi.org\/10.2217\/frd-2021-0008","journal-title":"Future Med"},{"issue":"5","key":"12269_CR126","doi-asserted-by":"crossref","first-page":"e135633","DOI":"10.1172\/jci.insight.135633","volume":"6","author":"TA Cole","year":"2021","unstructured":"Cole TA et al (2021) Alpha-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson\u2019s disease. JCI Insight 6(5):e135633","journal-title":"JCI Insight"},{"issue":"16","key":"12269_CR127","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.3390\/ijms21165724","volume":"21","author":"CA Morato Torres","year":"2020","unstructured":"Morato Torres CA et al (2020) The role of alpha-synuclein and other Parkinson\u2019s genes in neurodevelopmental and neurodegenerative disorders. Int J Mol Sci 21(16):5724","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12269_CR128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich A et al (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239\u2013252","journal-title":"Neuron"},{"key":"12269_CR129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neurobiolaging.2020.02.026","volume":"91","author":"N Ninkina","year":"2020","unstructured":"Ninkina N et al (2020) Alterations in the nigrostriatal system following conditional inactivation of alpha-synuclein in neurons of adult and aging mice. Neurobiol Aging 91:76\u201387","journal-title":"Neurobiol Aging"},{"issue":"6","key":"12269_CR130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","volume":"15","author":"DE Ehrnhoefer","year":"2008","unstructured":"Ehrnhoefer DE et al (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15(6):558\u2013566","journal-title":"Nat Struct Mol Biol"},{"issue":"17","key":"12269_CR131","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","volume":"107","author":"J Bieschke","year":"2010","unstructured":"Bieschke J et al (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107(17):7710\u20137715","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"12269_CR132","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","volume":"289","author":"N Lorenzen","year":"2014","unstructured":"Lorenzen N et al (2014) How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro. J Biol Chem 289(31):21299\u201321310","journal-title":"J Biol Chem"},{"key":"12269_CR133","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","volume":"286","author":"M Chen","year":"2015","unstructured":"Chen M et al (2015) Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral alpha-synuclein aggregation in MPTP-intoxicated Parkinsonian monkeys. Neuroscience 286:383\u2013392","journal-title":"Neuroscience"},{"issue":"8","key":"12269_CR134","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","volume":"18","author":"J Levin","year":"2019","unstructured":"Levin J et al (2019) Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 18(8):724\u2013735","journal-title":"Lancet Neurol"},{"issue":"Pt 12","key":"12269_CR135","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"W Wrasidlo","year":"2016","unstructured":"Wrasidlo W et al (2016) A de novo compound targeting alpha-synuclein improves deficits in models of Parkinson\u2019s disease. Brain 139(Pt 12):3217\u20133236","journal-title":"Brain"},{"issue":"1","key":"12269_CR136","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL et al (2018) The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep 8(1):16165","journal-title":"Sci Rep"},{"issue":"6","key":"12269_CR137","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J et al (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol 125(6):795\u2013813","journal-title":"Acta Neuropathol"},{"issue":"2","key":"12269_CR138","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2019","unstructured":"Heras-Garvin A et al (2019) Anle138b modulates alpha-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 34(2):255\u2013263","journal-title":"Mov Disord"},{"issue":"1","key":"12269_CR139","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40035-020-00217-y","volume":"9","author":"M Lemos","year":"2020","unstructured":"Lemos M et al (2020) Targeting alpha-synuclein by PD03 AFFITOPE(R) and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance. Transl Neurodegener 9(1):38","journal-title":"Transl Neurodegener"},{"issue":"Pt 4","key":"12269_CR140","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/114.4.1953","volume":"114","author":"DT Dexter","year":"1991","unstructured":"Dexter DT et al (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson\u2019s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953\u20131975","journal-title":"Brain"},{"issue":"4","key":"12269_CR141","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3233\/JAD-170601","volume":"61","author":"C Kaindlstorfer","year":"2018","unstructured":"Kaindlstorfer C et al (2018) The relevance of iron in the pathogenesis of multiple system atrophy: a viewpoint. J Alzheimers Dis 61(4):1253\u20131273","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"12269_CR142","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/WNR.0b013e328354a1f0","volume":"23","author":"F Febbraro","year":"2012","unstructured":"Febbraro F et al (2012) Alpha-synuclein expression is modulated at the translational level by iron. NeuroReport 23(9):576\u2013580","journal-title":"NeuroReport"},{"issue":"46","key":"12269_CR143","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","volume":"290","author":"C Follmer","year":"2015","unstructured":"Follmer C et al (2015) Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). J Biol Chem 290(46):27660\u201327679","journal-title":"J Biol Chem"},{"issue":"1","key":"12269_CR144","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","volume":"5","author":"DI Finkelstein","year":"2017","unstructured":"Finkelstein DI et al (2017) The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease. Acta Neuropathol Commun 5(1):53","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"12269_CR145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JPD-212877","volume":"12","author":"DI Finkelstein","year":"2022","unstructured":"Finkelstein DI et al (2022) The compound ATH434 prevents alpha-synuclein toxicity in a murine model of multiple system atrophy. J Parkinsons Dis 12(1):105\u2013115","journal-title":"J Parkinsons Dis"},{"key":"12269_CR146","doi-asserted-by":"crossref","unstructured":"David Stamler MB, Wong C, Offman E (2020) A phase 1 study of pbt434, a novel small molecule inhibitor of \u03b1-synuclein aggregation, in adult and older adult volunteers (4871). Neurology, 9 4","DOI":"10.1212\/WNL.94.15_supplement.4871"},{"key":"12269_CR147","unstructured":"de Natale A, Terry H, Wilson J, Verghese G, Pagano P, Khosropanah M, Howard H, Wright L, Cashmore L, Passamonti M, Hutchison K, Evans Y, Lewis E, Politis RM (2023) An in-vivo study of regional synaptic density loss in patients with Multiple System Atrophy using [11C]UCB-J PET molecular imaging. Mov Disord. Available from: https:\/\/www.mdsabstracts.org\/abstract\/an-in-vivo-study-of-regional-synaptic-density-loss-in-patients-with-multiple-system-atrophy-using-11cucb-j-pet-molecular-imaging\/"},{"issue":"5575","key":"12269_CR148","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1126\/science.1067122","volume":"296","author":"JP Taylor","year":"2002","unstructured":"Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296(5575):1991\u20131995","journal-title":"Science"},{"issue":"2","key":"12269_CR149","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","volume":"40","author":"A Ciechanover","year":"2003","unstructured":"Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40(2):427\u2013446","journal-title":"Neuron"},{"issue":"6","key":"12269_CR150","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrn3961","volume":"16","author":"FM Menzies","year":"2015","unstructured":"Menzies FM, Fleming A, Rubinsztein DC (2015) Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci 16(6):345\u2013357","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"12269_CR151","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10286-019-00662-4","volume":"30","author":"A Ndayisaba","year":"2020","unstructured":"Ndayisaba A, Wenning GK (2020) Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. Clin Auton Res 30(1):7\u20138","journal-title":"Clin Auton Res"},{"issue":"8","key":"12269_CR152","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn3068","volume":"12","author":"J Bove","year":"2011","unstructured":"Bove J, Martinez-Vicente M, Vila M (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12(8):437\u2013452","journal-title":"Nat Rev Neurosci"},{"key":"12269_CR153","doi-asserted-by":"crossref","first-page":"559791","DOI":"10.3389\/fcell.2020.559791","volume":"8","author":"M Fouka","year":"2020","unstructured":"Fouka M et al (2020) In search of effective treatments targeting alpha-synuclein toxicity in synucleinopathies: pros and cons. Front Cell Dev Biol 8:559791","journal-title":"Front Cell Dev Biol"},{"key":"12269_CR154","unstructured":"Lopez-Cuina M, Guerin P, Bezard E, Meissner W, Fernagut P-O (2018) Rapamycin for treating MSA: a preclinical proof of concept study. Int Parkinson Movement Disord Soc"},{"issue":"11","key":"12269_CR155","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","volume":"11","author":"J Li","year":"2004","unstructured":"Li J et al (2004) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11(11):1513\u20131521","journal-title":"Chem Biol"},{"issue":"13","key":"12269_CR156","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/WNR.0b013e32830b3661","volume":"19","author":"K Ubhi","year":"2008","unstructured":"Ubhi K et al (2008) Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. NeuroReport 19(13):1271\u20131276","journal-title":"NeuroReport"},{"key":"12269_CR157","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12868-015-0222-y","volume":"16","author":"L Hou","year":"2015","unstructured":"Hou L et al (2015) Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement. BMC Neurosci 16:82","journal-title":"BMC Neurosci"},{"issue":"2","key":"12269_CR158","first-page":"73","volume":"123","author":"XZ Li","year":"2013","unstructured":"Li XZ et al (2013) Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. Int J Neurosci 123(2):73\u201379","journal-title":"Int J Neurosci"},{"issue":"2","key":"12269_CR159","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00415-012-6655-7","volume":"260","author":"F Sacca","year":"2013","unstructured":"Sacca F et al (2013) A randomized clinical trial of lithium in multiple system atrophy. J Neurol 260(2):458\u2013461","journal-title":"J Neurol"},{"issue":"48","key":"12269_CR160","doi-asserted-by":"crossref","first-page":"33855","DOI":"10.1074\/jbc.274.48.33855","volume":"274","author":"MC Bennett","year":"1999","unstructured":"Bennett MC et al (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274(48):33855\u201333858","journal-title":"J Biol Chem"},{"issue":"6","key":"12269_CR161","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.chembiol.2020.05.012","volume":"27","author":"J Qu","year":"2020","unstructured":"Qu J et al (2020) Specific knockdown of alpha-synuclein by peptide-directed proteasome degradation rescued its associated neurotoxicity. Cell Chem Biol 27(6):763","journal-title":"Cell Chem Biol"},{"issue":"3","key":"12269_CR162","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bpa.12678","volume":"29","author":"A Hoffmann","year":"2019","unstructured":"Hoffmann A et al (2019) Oligodendroglial alpha-synucleinopathy-driven neuroinflammation in multiple system atrophy. Brain Pathol 29(3):380\u2013396","journal-title":"Brain Pathol"},{"issue":"1","key":"12269_CR163","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jnen\/63.1.43","volume":"63","author":"K Ishizawa","year":"2004","unstructured":"Ishizawa K et al (2004) Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 63(1):43\u201352","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"12269_CR164","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/01.STR.0000206281.77178.ac","volume":"37","author":"MA Yenari","year":"2006","unstructured":"Yenari MA et al (2006) Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 37(4):1087\u20131093","journal-title":"Stroke"},{"issue":"1","key":"12269_CR165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/glia.20051","volume":"48","author":"JK Ryu","year":"2004","unstructured":"Ryu JK et al (2004) Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 48(1):85\u201390","journal-title":"Glia"},{"issue":"2","key":"12269_CR166","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, Galvez J (2013) Minocycline: far beyond an antibiotic. Br J Pharmacol 169(2):337\u2013352","journal-title":"Br J Pharmacol"},{"issue":"2","key":"12269_CR167","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbr.2008.09.040","volume":"196","author":"HS Kim","year":"2009","unstructured":"Kim HS, Suh YH (2009) Minocycline and neurodegenerative diseases. Behav Brain Res 196(2):168\u2013179","journal-title":"Behav Brain Res"},{"issue":"12","key":"12269_CR168","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1474-4422(04)00937-8","volume":"3","author":"VW Yong","year":"2004","unstructured":"Yong VW et al (2004) The promise of minocycline in neurology. Lancet Neurol 3(12):744\u2013751","journal-title":"Lancet Neurol"},{"issue":"1","key":"12269_CR169","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jnr.20233","volume":"78","author":"N Stefanova","year":"2004","unstructured":"Stefanova N et al (2004) Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 78(1):87\u201391","journal-title":"J Neurosci Res"},{"issue":"2","key":"12269_CR170","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jnr.10709","volume":"74","author":"L Yang","year":"2003","unstructured":"Yang L et al (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 74(2):278\u2013285","journal-title":"J Neurosci Res"},{"issue":"1","key":"12269_CR171","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/mds.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R et al (2010) Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25(1):97\u2013107","journal-title":"Mov Disord"},{"issue":"6","key":"12269_CR172","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/mds.21259","volume":"22","author":"AJ Langerveld","year":"2007","unstructured":"Langerveld AJ et al (2007) Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. Mov Disord 22(6):766\u2013777","journal-title":"Mov Disord"},{"key":"12269_CR173","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2377-12-131","volume":"12","author":"P Novak","year":"2012","unstructured":"Novak P et al (2012) Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 12:131","journal-title":"BMC Neurol"},{"issue":"3","key":"12269_CR174","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1471-4159.2004.02527.x","volume":"90","author":"PS Green","year":"2004","unstructured":"Green PS et al (2004) Neuronal expression of myeloperoxidase is increased in Alzheimer\u2019s disease. J Neurochem 90(3):724\u2013733","journal-title":"J Neurochem"},{"issue":"28","key":"12269_CR175","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1523\/JNEUROSCI.0970-05.2005","volume":"25","author":"DK Choi","year":"2005","unstructured":"Choi DK et al (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson\u2019s disease in mice. J Neurosci 25(28):6594\u20136600","journal-title":"J Neurosci"},{"issue":"1","key":"12269_CR176","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1750-3639.2007.00110.x","volume":"18","author":"E Gray","year":"2008","unstructured":"Gray E et al (2008) Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol 18(1):86\u201395","journal-title":"Brain Pathol"},{"issue":"4","key":"12269_CR177","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12640-011-9294-3","volume":"21","author":"N Stefanova","year":"2012","unstructured":"Stefanova N et al (2012) Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res 21(4):393\u2013404","journal-title":"Neurotox Res"},{"issue":"3","key":"12269_CR178","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12640-015-9547-7","volume":"28","author":"C Kaindlstorfer","year":"2015","unstructured":"Kaindlstorfer C et al (2015) Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: clinical implications. Neurotox Res 28(3):185\u2013194","journal-title":"Neurotox Res"},{"issue":"11","key":"12269_CR179","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/jcph.1134","volume":"58","author":"X Tong","year":"2018","unstructured":"Tong X et al (2018) Population pharmacokinetic modeling with enterohepatic circulation for AZD3241 in healthy subjects and patients with multiple system atrophy. J Clin Pharmacol 58(11):1452\u20131460","journal-title":"J Clin Pharmacol"},{"issue":"Pt 9","key":"12269_CR180","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awv184","volume":"138","author":"A Jucaite","year":"2015","unstructured":"Jucaite A et al (2015) Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson\u2019s disease. Brain 138(Pt 9):2687\u20132700","journal-title":"Brain"},{"issue":"1","key":"12269_CR181","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2967\/jnumed.109.068064","volume":"51","author":"Y Fujimura","year":"2010","unstructured":"Fujimura Y et al (2010) Biodistribution and radiation dosimetry in humans of a new PET ligand, (18)F-PBR06, to image translocator protein (18 kDa). J Nucl Med 51(1):145\u2013149","journal-title":"J Nucl Med"},{"issue":"18","key":"12269_CR182","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2174\/092986710791163939","volume":"17","author":"BC Cheah","year":"2010","unstructured":"Cheah BC et al (2010) Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 17(18):1942\u20132199","journal-title":"Curr Med Chem"},{"issue":"8","key":"12269_CR183","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00702-004-0245-5","volume":"112","author":"C Scherfler","year":"2005","unstructured":"Scherfler C et al (2005) Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). J Neural Transm (Vienna) 112(8):1025\u20131033","journal-title":"J Neural Transm (Vienna)"},{"issue":"10","key":"12269_CR184","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1468-1331.2006.01452.x","volume":"13","author":"K Seppi","year":"2006","unstructured":"Seppi K et al (2006) Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 13(10):1146\u20131148","journal-title":"Eur J Neurol"},{"issue":"Pt 1","key":"12269_CR185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","volume":"132","author":"G Bensimon","year":"2009","unstructured":"Bensimon G et al (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132(Pt 1):156\u2013171","journal-title":"Brain"},{"issue":"3","key":"12269_CR186","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/14734220510008003","volume":"4","author":"A Sanchez-Perez","year":"2005","unstructured":"Sanchez-Perez A et al (2005) Modulation of NMDA receptors in the cerebellum II. Signaling pathways and physiological modulators regulating NMDA receptor function. Cerebellum 4(3):162\u2013170","journal-title":"Cerebellum"},{"issue":"3","key":"12269_CR187","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nbd.2008.05.006","volume":"31","author":"R Betarbet","year":"2008","unstructured":"Betarbet R et al (2008) Fas-associated factor 1 and Parkinson\u2019s disease. Neurobiol Dis 31(3):309\u2013315","journal-title":"Neurobiol Dis"},{"issue":"8","key":"12269_CR188","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/hmg\/ddt006","volume":"22","author":"JW Sul","year":"2013","unstructured":"Sul JW et al (2013) Accumulation of the parkin substrate, FAF1, plays a key role in the dopaminergic neurodegeneration. Hum Mol Genet 22(8):1558\u20131573","journal-title":"Hum Mol Genet"},{"issue":"4","key":"12269_CR189","doi-asserted-by":"crossref","first-page":"e21363","DOI":"10.1096\/fj.202001371RR","volume":"35","author":"BS Kim","year":"2021","unstructured":"Kim BS et al (2021) Fas-associated factor 1 induces the accumulation of alpha-synuclein through autophagic suppression in dopaminergic neurons. FASEB J 35(4):e21363","journal-title":"FASEB J"},{"key":"12269_CR190","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fphar.2020.00953","volume":"11","author":"HS Park","year":"2020","unstructured":"Park HS et al (2020) Neurorestorative effects of a novel fas-associated factor 1 inhibitor in the MPTP model: an [(18)F]FE-PE2I positron emission tomography analysis study. Front Pharmacol 11:953","journal-title":"Front Pharmacol"},{"issue":"6","key":"12269_CR191","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1021\/acschemneuro.1c00828","volume":"13","author":"BS Kim","year":"2022","unstructured":"Kim BS et al (2022) Pharmacological intervention targeting FAF1 restores autophagic flux for alpha-synuclein degradation in the brain of a parkinson\u2019s disease mouse model. ACS Chem Neurosci 13(6):806\u2013817","journal-title":"ACS Chem Neurosci"},{"key":"12269_CR192","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/DDDT.S198753","volume":"13","author":"W Shin","year":"2019","unstructured":"Shin W et al (2019) A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson\u2019s disease, in healthy volunteers. Drug Des Devel Ther 13:1011\u20131022","journal-title":"Drug Des Devel Ther"},{"key":"12269_CR193","unstructured":"Therapeutics F (2021) FAScinate Therapeutics, Inc. cleared for phase 2 clinical trials of company\u2019s Parkinson\u2019s disease treatment with approval from U.S. Food and Drug Administration. 2021 November 17, 2021. Available from: https:\/\/www.fascinatetherapeutics.com\/news\/fascinate-therapeutics-inc.-cleared-for-phase-2-clinical-trials-of-companys-parkinsons-disease-treatment-with-approval-from-u.s.-food-and-drug-administration-1"},{"issue":"4","key":"12269_CR194","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","volume":"37","author":"R Sharon","year":"2003","unstructured":"Sharon R et al (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease. Neuron 37(4):583\u2013595","journal-title":"Neuron"},{"issue":"5","key":"12269_CR195","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","volume":"73","author":"S Fanning","year":"2019","unstructured":"Fanning S et al (2019) Lipidomic analysis of alpha-synuclein neurotoxicity identifies stearoyl coa desaturase as a target for parkinson treatment. Mol Cell 73(5):1001-1014 e8","journal-title":"Mol Cell"},{"issue":"15","key":"12269_CR196","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.3390\/ijms21155193","volume":"21","author":"E Terry-Kantor","year":"2020","unstructured":"Terry-Kantor E et al (2020) Rapid alpha-synuclein toxicity in a neural cell model and its rescue by a stearoyl-CoA desaturase inhibitor. Int J Mol Sci 21(15):5193","journal-title":"Int J Mol Sci"},{"issue":"10","key":"12269_CR197","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.celrep.2018.11.028","volume":"25","author":"BM Vincent","year":"2018","unstructured":"Vincent BM et al (2018) Inhibiting stearoyl-CoA desaturase ameliorates alpha-synuclein cytotoxicity. Cell Rep 25(10):2742\u20132754","journal-title":"Cell Rep"},{"key":"#cr-split#-12269_CR198.1","unstructured":"Therapeutics Y (2021) Yumanity Therapeutics announces positive top-line results of phase 1b clinical trial for YTX-7739 in Patients with Parkinson's Disease"},{"key":"#cr-split#-12269_CR198.2","unstructured":"company plans to advance program to phase 2. 2021 Nov 10 2021. Available from: https:\/\/yumanity.gcs-web.com\/node\/10026\/pdf"},{"issue":"5","key":"12269_CR199","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.stemcr.2018.09.007","volume":"11","author":"G Monzio Compagnoni","year":"2018","unstructured":"Monzio Compagnoni G et al (2018) Mitochondrial dysregulation and impaired autophagy in iPSC-derived dopaminergic neurons of multiple system atrophy. Stem Cell Reports 11(5):1185\u20131198","journal-title":"Stem Cell Reports"},{"issue":"1","key":"12269_CR200","doi-asserted-by":"crossref","first-page":"14215","DOI":"10.1038\/s41598-018-32573-1","volume":"8","author":"FK Nakamoto","year":"2018","unstructured":"Nakamoto FK et al (2018) The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. Sci Rep 8(1):14215","journal-title":"Sci Rep"},{"issue":"3","key":"12269_CR201","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","volume":"16","author":"J Mitsui","year":"2017","unstructured":"Mitsui J et al (2017) Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations. Cerebellum 16(3):664\u2013672","journal-title":"Cerebellum"},{"key":"12269_CR202","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101920","volume":"59","author":"J Mitsui","year":"2023","unstructured":"Mitsui J et al (2023) High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. EClinicalMedicine 59:101920","journal-title":"EClinicalMedicine"},{"issue":"3","key":"12269_CR203","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1210\/en.2002-220667","volume":"144","author":"R Ajo","year":"2003","unstructured":"Ajo R et al (2003) Growth hormone action on proliferation and differentiation of cerebral cortical cells from fetal rat. Endocrinology 144(3):1086\u20131097","journal-title":"Endocrinology"},{"issue":"8","key":"12269_CR204","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.21501","volume":"22","author":"B Holmberg","year":"2007","unstructured":"Holmberg B et al (2007) Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 22(8):1138\u20131144","journal-title":"Mov Disord"},{"issue":"3","key":"12269_CR205","first-page":"467","volume":"3","author":"S Lecht","year":"2007","unstructured":"Lecht S et al (2007) Rasagiline\u2014a novel MAO B inhibitor in Parkinson\u2019s disease therapy. Ther Clin Risk Manag 3(3):467\u2013474","journal-title":"Ther Clin Risk Manag"},{"issue":"13","key":"12269_CR206","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med 361(13):1268\u20131278","journal-title":"N Engl J Med"},{"issue":"2","key":"12269_CR207","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.expneurol.2007.11.022","volume":"210","author":"N Stefanova","year":"2008","unstructured":"Stefanova N, Poewe W, Wenning GK (2008) Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 210(2):421\u2013427","journal-title":"Exp Neurol"},{"issue":"2","key":"12269_CR208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","volume":"14","author":"W Poewe","year":"2015","unstructured":"Poewe W et al (2015) Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 14(2):145\u2013152","journal-title":"Lancet Neurol"},{"issue":"2","key":"12269_CR209","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","volume":"234","author":"K Ubhi","year":"2012","unstructured":"Ubhi K et al (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp Neurol 234(2):405\u2013416","journal-title":"Exp Neurol"},{"issue":"(01)","key":"12269_CR210","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/S1353-8020(11)70066-9","volume":"18 Supp 1","author":"F Zhang","year":"2012","unstructured":"Zhang F et al (2012) Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord 18 Supp 1((01)):S213\u2013S217","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"12269_CR211","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/mds.28569","volume":"36","author":"O Rascol","year":"2021","unstructured":"Rascol O et al (2021) Fluoxetine for the symptomatic treatment of multiple system atrophy: the MSA-FLUO Trial. Mov Disord 36(7):1704\u20131711","journal-title":"Mov Disord"},{"issue":"2","key":"12269_CR212","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2011-1802","volume":"97","author":"E Shemesh","year":"2012","unstructured":"Shemesh E et al (2012) Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 97(2):366\u2013376","journal-title":"J Clin Endocrinol Metab"},{"key":"12269_CR213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","volume":"118","author":"F Bassil","year":"2014","unstructured":"Bassil F et al (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 118:1\u201318","journal-title":"Prog Neurobiol"},{"issue":"15","key":"12269_CR214","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/mds.23320","volume":"25","author":"MT Pellecchia","year":"2010","unstructured":"Pellecchia MT et al (2010) Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. Mov Disord 25(15):2621\u20132626","journal-title":"Mov Disord"},{"issue":"2","key":"12269_CR215","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.parkreldis.2013.11.005","volume":"20","author":"A Numao","year":"2014","unstructured":"Numao A et al (2014) Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson\u2019s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 20(2):212\u2013216","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"12269_CR216","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/brain\/awx044","volume":"140","author":"F Bassil","year":"2017","unstructured":"Bassil F et al (2017) Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 140(5):1420\u20131436","journal-title":"Brain"},{"issue":"4","key":"12269_CR217","doi-asserted-by":"crossref","first-page":"0214364","DOI":"10.1371\/journal.pone.0214364","volume":"14","author":"P Novak","year":"2019","unstructured":"Novak P, Maldonado DAP, Novak V (2019) Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study. PLoS ONE 14(4):0214364","journal-title":"PLoS ONE"},{"issue":"1","key":"12269_CR218","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1038\/s41467-022-32447-1","volume":"13","author":"E Lyapina","year":"2022","unstructured":"Lyapina E et al (2022) Structural basis for receptor selectivity and inverse agonism in S1P(5) receptors. Nat Commun 13(1):4736","journal-title":"Nat Commun"},{"issue":"5","key":"12269_CR219","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/jcb.20886","volume":"98","author":"AI Caplan","year":"2006","unstructured":"Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98(5):1076\u20131084","journal-title":"J Cell Biochem"},{"issue":"3","key":"12269_CR220","doi-asserted-by":"crossref","first-page":"e0213032","DOI":"10.1371\/journal.pone.0213032","volume":"14","author":"DN Urrutia","year":"2019","unstructured":"Urrutia DN et al (2019) Comparative study of the neural differentiation capacity of mesenchymal stromal cells from different tissue sources: an approach for their use in neural regeneration therapies. PLoS ONE 14(3):e0213032","journal-title":"PLoS ONE"},{"issue":"5","key":"12269_CR221","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1002\/jcp.26192","volume":"233","author":"D Lo Furno","year":"2018","unstructured":"Lo Furno D, Mannino G, Giuffrida R (2018) Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. J Cell Physiol 233(5):3982\u20133999","journal-title":"J Cell Physiol"},{"issue":"5","key":"12269_CR222","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.mayocp.2019.01.001","volume":"94","author":"NP Staff","year":"2019","unstructured":"Staff NP, Jones DT, Singer W (2019) Mesenchymal stromal cell therapies for neurodegenerative diseases. Mayo Clin Proc 94(5):892\u2013905","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"12269_CR223","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3727\/096368910X540630","volume":"20","author":"HJ Park","year":"2011","unstructured":"Park HJ et al (2011) Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism. Cell Transplant 20(6):827\u2013835","journal-title":"Cell Transplant"},{"issue":"5","key":"12269_CR224","doi-asserted-by":"crossref","first-page":"e19808","DOI":"10.1371\/journal.pone.0019808","volume":"6","author":"S Stemberger","year":"2011","unstructured":"Stemberger S et al (2011) Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. PLoS ONE 6(5):e19808","journal-title":"PLoS ONE"},{"issue":"5","key":"12269_CR225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.clpt.6100386","volume":"83","author":"PH Lee","year":"2008","unstructured":"Lee PH et al (2008) Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 83(5):723\u2013730","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"12269_CR226","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ana.23655","volume":"72","author":"PA Low","year":"2012","unstructured":"Low PA, Gilman S (2012) Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Ann Neurol 72(1):4\u20135","journal-title":"Ann Neurol"},{"issue":"1","key":"12269_CR227","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.23612","volume":"72","author":"PH Lee","year":"2012","unstructured":"Lee PH et al (2012) A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 72(1):32\u201340","journal-title":"Ann Neurol"},{"issue":"1","key":"12269_CR228","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/WNL.0000000000007720","volume":"93","author":"W Singer","year":"2019","unstructured":"Singer W et al (2019) Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 93(1):e77\u2013e87","journal-title":"Neurology"},{"issue":"12","key":"12269_CR229","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/mds.25174","volume":"27","author":"WG Meissner","year":"2012","unstructured":"Meissner WG et al (2012) Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disord 27(12):1574\u20131577","journal-title":"Mov Disord"},{"key":"12269_CR230","doi-asserted-by":"crossref","first-page":"980371","DOI":"10.3389\/fpsyt.2022.980371","volume":"13","author":"Q Lv","year":"2022","unstructured":"Lv Q et al (2022) Depression in multiple system atrophy: views on pathological, clinical and imaging aspects. Front Psychiatry 13:980371","journal-title":"Front Psychiatry"},{"issue":"6","key":"12269_CR231","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10286-022-00898-7","volume":"32","author":"EP Golden","year":"2022","unstructured":"Golden EP, McCreary M, Vernino S (2022) Responsiveness of UMSARS and other clinical measures in a longitudinal structured care clinic for multiple system atrophy. Clin Auton Res 32(6):477\u2013484","journal-title":"Clin Auton Res"},{"issue":"1","key":"12269_CR232","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12967-023-03905-1","volume":"21","author":"FS Tseng","year":"2023","unstructured":"Tseng FS et al (2023) The genetic basis of multiple system atrophy. J Transl Med 21(1):104","journal-title":"J Transl Med"},{"issue":"4","key":"12269_CR233","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson 3rd","year":"2023","unstructured":"Wilson DM 3rd et al (2023) Hallmarks of neurodegenerative diseases. Cell 186(4):693\u2013714","journal-title":"Cell"},{"issue":"3","key":"12269_CR234","doi-asserted-by":"crossref","first-page":"20211057","DOI":"10.1084\/jem.20211057","volume":"219","author":"A Arguello","year":"2022","unstructured":"Arguello A et al (2022) Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme. J Exp Med 219(3):20211057","journal-title":"J Exp Med"},{"issue":"11","key":"12269_CR235","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jnen\/nly090","volume":"77","author":"F Li","year":"2018","unstructured":"Li F et al (2018) NLRP3 Inflammasome-related proteins are upregulated in the putamen of patients with multiple system atrophy. J Neuropathol Exp Neurol 77(11):1055\u20131065","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12269-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12269-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12269-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:37:55Z","timestamp":1731555475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12269-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":236,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["12269"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12269-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All authors have no financial relationships to disclose relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}